Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
Columvi avoids its worst-case scenario
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
AbbVie gets a cMet niche
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
